Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Inova Health Care Services
This is a double-blind randomized clinical trial of evolocumab versus placebo in patients with ASCVD and DM on clopidogrel and aspirin undergoing PCI. The study is aimed to assess
1. the effect of evolocumab therapy on platelet activation and reactivity;
2. the effect of evolocumab on biomarkers of platelet activation and inflammation.
Eligible patients will be randomized prior to start the PCI equally to either:
1. 420 mg evolocumab ; or
2. placebo. The randomized treatment will be administered in subcutaneous injections.
The laboratory assessments will be performed before (baseline), and 16-24 hours and 30-days after randomization.
Subject participation will be 30 days from the randomization.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diabetes Mellitus
Dyslipidemia
Undergoing elective PCI
You may not be if
Patients with recent Acute Coronary Syndrome (≤1 month)
Patients on dual antiplatelet treatment (DAPT) with ticagrelor or prasugrel
Patients undergoing urgent/emergent PCI for stent thrombosis
Severe acute or chronic medical or psychiatric condition
Pregnancy
Participation in another experimental clinical trial, without formal approval
Unwillingness or inability to comply with the requirements of this protocol